BIOTRON LIMITED - Announcements

Market Cap $18.04M Add to my watchlist

Healthcare Biotechnology

Biotron Limited is an Australia-based biotechnology company. The Company is primarily... Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/24	1.07MB	Share
BIT	Typographical error		25/10/24	125.47KB	Share
BIT	Option Expiry Notice		24/10/24	901.37KB	Share
BIT	Annual Report/Notice of AGM/Proxy Form		22/10/24	2.42MB	Share
BIT	$1.8M R&D Rebate Received	PRICE SENSITIVE	14/10/24	399.28KB	Share
BIT	Response to ASX Aware Query	PRICE SENSITIVE	25/09/24	1.5MB	Share
BIT	BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL	PRICE SENSITIVE	06/09/24	540.68KB	Share
BIT	Appendix 4G		30/08/24	264.8KB	Share
BIT	Corporate Governance Statement		30/08/24	216.37KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	30/08/24	1.41MB	Share
BIT	Application for quotation of securities - BIT		15/08/24	15.36KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	1.01MB	Share
BIT	Application for quotation of securities - BIT		22/07/24	15.35KB	Share
BIT	Letter to Shareholders		11/07/24	1006.55KB	Share
BIT	Webinar Investors Presentation		26/06/24	3.99MB	Share
BIT	BIOTRON CLINICAL TRIAL RESULTS WEBINAR		25/06/24	828.97KB	Share
BIT	BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives	PRICE SENSITIVE	19/06/24	711.16KB	Share
BIT	Change of Share Registry address		23/05/24	95.43KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/04/24	1MB	Share
BIT	POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV	PRICE SENSITIVE	05/04/24	670.99KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	27/03/24	453.67KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/24	603.88KB	Share
BIT	$1.64M R&D rebate received		08/02/24	269.89KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/24	277.88KB	Share
BIT	Shareholder Update		14/12/23	127.05KB	Share
BIT	Application for quotation of securities - BIT		01/12/23	24.61KB	Share
BIT	Change of Director's Interest Notice MM		27/11/23	197.97KB	Share
BIT	Notification of cessation of securities - BIT		27/11/23	21.45KB	Share
BIT	Results of AGM		22/11/23	92.59KB	Share
BIT	Presentation to Annual General Meeting		22/11/23	1.58MB	Share
BIT	Application for quotation of securities - BIT		10/11/23	24.66KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	1.03MB	Share
BIT	Application for quotation of securities - BIT		26/10/23	24.66KB	Share
BIT	Presentation to Investors		24/10/23	979.37KB	Share
BIT	Annual Report/Notice of Annual General Meeting/Proxy Form		20/10/23	1.33MB	Share
BIT	Application for quotation of securities - BIT		10/10/23	24.66KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	29/09/23	712.55KB	Share
BIT	Letter to Shareholders		26/09/23	373.27KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	11/09/23	665.15KB	Share
BIT	Appendix 4G		25/08/23	256.42KB	Share
BIT	Corporate Governance Statement		25/08/23	213.39KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	25/08/23	1.05MB	Share
BIT	COMPLETION OF PHASE 2 COVID CLINICAL TRIAL	PRICE SENSITIVE	16/08/23	312.28KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	475.77KB	Share
BIT	Second Site Approved for Phase 2 Covid-19 Trial	PRICE SENSITIVE	12/05/23	89.11KB	Share
BIT	Commencement Phase 2 Covid-19 Clinical Trial	PRICE SENSITIVE	04/05/23	144.72KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	1.01MB	Share
BIT	Cleansing Notice		22/03/23	99.09KB	Share
BIT	Application for quotation of securities - BIT		22/03/23	24.65KB	Share
BIT	Completion of Phase 2 HIV-1 Clinical Trials	PRICE SENSITIVE	09/03/23	403.58KB	Share
BIT	International Presentation of BIT225 COVID-19 Data	PRICE SENSITIVE	21/02/23	824.33KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	17/02/23	794.46KB	Share
BIT	Notification of cessation of securities - BIT		01/02/23	21.47KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	436.71KB	Share
BIT	CLEANSING NOTICE		25/01/23	262.54KB	Share
BIT	Application for quotation of securities - BIT		25/01/23	24.68KB	Share
BIT	Change of Director's Interest Notice		29/11/22	250.15KB	Share
BIT	Notification of cessation of securities - BIT		28/11/22	21.5KB	Share
BIT	Cleansing Notice		25/11/22	97.91KB	Share
BIT	Listed Options Information		25/11/22	98.9KB	Share
BIT	Application for quotation of securities		25/11/22	358.97KB	Share
BIT	Application for quotation of securities - BIT		25/11/22	29.22KB	Share
BIT	Proposed issue of securities - BIT		24/11/22	27.45KB	Share
BIT	Rights Issue Closed	PRICE SENSITIVE	24/11/22	174.24KB	Share
BIT	Supplementary Prospectus	PRICE SENSITIVE	24/11/22	139.65KB	Share
BIT	Cancel - Proposed issue of securities - BIT		22/11/22	38.86KB	Share
BIT	Appendix 3B		21/11/22	753.77KB	Share
BIT	$1.43M R&D rebate received	PRICE SENSITIVE	18/11/22	148.2KB	Share
BIT	Results of Annual General Meeting		16/11/22	173.02KB	Share
BIT	Chairman's Address and Presentation to AGM		16/11/22	370.97KB	Share
BIT	Presentation to Investors		11/11/22	408.74KB	Share
BIT	Clarification of Fractional Entitlements		07/11/22	112.37KB	Share
BIT	Commencement of Rights Trading - BITRC	PRICE SENSITIVE	31/10/22	128.29KB	Share
BIT	Letter to Shareholders		31/10/22	370.18KB	Share
BIT	Prospectus	PRICE SENSITIVE	27/10/22	683.43KB	Share
BIT	Renounceable Issue	PRICE SENSITIVE	27/10/22	190.28KB	Share
BIT	Proposed issue of securities - BIT		27/10/22	39.21KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/10/22	422.98KB	Share
BIT	Annual Report and Notice of Annual General Meeting		14/10/22	2.98MB	Share
BIT	Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	04/10/22	181.16KB	Share
BIT	Bit225 Covid-19 Human Study Commenced	PRICE SENSITIVE	14/09/22	175.41KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	23/08/22	154.11KB	Share
BIT	Appendix 4G and Corporate Governance Statement		19/08/22	638.34KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	19/08/22	670.98KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/22	1.04MB	Share
BIT	POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM	PRICE SENSITIVE	30/05/22	130.47KB	Share
BIT	BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS	PRICE SENSITIVE	02/05/22	353.01KB	Share
BIT	Quarterly Cash Flow Report Appendix 4C	PRICE SENSITIVE	26/04/22	250.36KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	26/04/22	137.32KB	Share
BIT	$1.56M R&D Rebate Received	PRICE SENSITIVE	05/04/22	147.99KB	Share
BIT	BIT225 Effectiveness Against COVID-19 in Animals	PRICE SENSITIVE	17/03/22	214.51KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/22	630.82KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	135.98KB	Share
BIT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	248.82KB	Share
BIT	Update on Biotron HIV-1 And COVID-19 Programs		16/12/21	406.87KB	Share
BIT	Notification of cessation of securities - BIT		06/12/21	21.5KB	Share
BIT	BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS	PRICE SENSITIVE	25/11/21	594.07KB	Share
BIT	Results of Meeting		23/11/21	159.5KB	Share
BIT	Chairman's Address and Presentation to AGM		23/11/21	482.81KB	Share
BIT	COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS	PRICE SENSITIVE	01/11/21	157.65KB	Share

BIT Quarterly Activities/Appendix 4C Cash Flow Report
30/10/24	PRICE SENSITIVE	1.07MB	Share
BIT Typographical error
25/10/24		125.47KB	Share
BIT Option Expiry Notice
24/10/24		901.37KB	Share
BIT Annual Report/Notice of AGM/Proxy Form
22/10/24		2.42MB	Share
BIT $1.8M R&D Rebate Received
14/10/24	PRICE SENSITIVE	399.28KB	Share
BIT Response to ASX Aware Query
25/09/24	PRICE SENSITIVE	1.5MB	Share
BIT BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL
06/09/24	PRICE SENSITIVE	540.68KB	Share
BIT Appendix 4G
30/08/24		264.8KB	Share
BIT Corporate Governance Statement
30/08/24		216.37KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
30/08/24	PRICE SENSITIVE	1.41MB	Share
BIT Application for quotation of securities - BIT
15/08/24		15.36KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	1.01MB	Share
BIT Application for quotation of securities - BIT
22/07/24		15.35KB	Share
BIT Letter to Shareholders
11/07/24		1006.55KB	Share
BIT Webinar Investors Presentation
26/06/24		3.99MB	Share
BIT BIOTRON CLINICAL TRIAL RESULTS WEBINAR
25/06/24		828.97KB	Share
BIT BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
19/06/24	PRICE SENSITIVE	711.16KB	Share
BIT Change of Share Registry address
23/05/24		95.43KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
26/04/24	PRICE SENSITIVE	1MB	Share
BIT POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV
05/04/24	PRICE SENSITIVE	670.99KB	Share
BIT Response to ASX Price Query
27/03/24	PRICE SENSITIVE	453.67KB	Share
BIT Half Yearly Report and Accounts
27/02/24	PRICE SENSITIVE	603.88KB	Share
BIT $1.64M R&D rebate received
08/02/24		269.89KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
30/01/24	PRICE SENSITIVE	277.88KB	Share
BIT Shareholder Update
14/12/23		127.05KB	Share
BIT Application for quotation of securities - BIT
01/12/23		24.61KB	Share
BIT Change of Director's Interest Notice MM
27/11/23		197.97KB	Share
BIT Notification of cessation of securities - BIT
27/11/23		21.45KB	Share
BIT Results of AGM
22/11/23		92.59KB	Share
BIT Presentation to Annual General Meeting
22/11/23		1.58MB	Share
BIT Application for quotation of securities - BIT
10/11/23		24.66KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	1.03MB	Share
BIT Application for quotation of securities - BIT
26/10/23		24.66KB	Share
BIT Presentation to Investors
24/10/23		979.37KB	Share
BIT Annual Report/Notice of Annual General Meeting/Proxy Form
20/10/23		1.33MB	Share
BIT Application for quotation of securities - BIT
10/10/23		24.66KB	Share
BIT Response to ASX Price Query
29/09/23	PRICE SENSITIVE	712.55KB	Share
BIT Letter to Shareholders
26/09/23		373.27KB	Share
BIT Response to ASX Price Query
11/09/23	PRICE SENSITIVE	665.15KB	Share
BIT Appendix 4G
25/08/23		256.42KB	Share
BIT Corporate Governance Statement
25/08/23		213.39KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
25/08/23	PRICE SENSITIVE	1.05MB	Share
BIT COMPLETION OF PHASE 2 COVID CLINICAL TRIAL
16/08/23	PRICE SENSITIVE	312.28KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	475.77KB	Share
BIT Second Site Approved for Phase 2 Covid-19 Trial
12/05/23	PRICE SENSITIVE	89.11KB	Share
BIT Commencement Phase 2 Covid-19 Clinical Trial
04/05/23	PRICE SENSITIVE	144.72KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	1.01MB	Share
BIT Cleansing Notice
22/03/23		99.09KB	Share
BIT Application for quotation of securities - BIT
22/03/23		24.65KB	Share
BIT Completion of Phase 2 HIV-1 Clinical Trials
09/03/23	PRICE SENSITIVE	403.58KB	Share
BIT International Presentation of BIT225 COVID-19 Data
21/02/23	PRICE SENSITIVE	824.33KB	Share
BIT Half Yearly Report and Accounts
17/02/23	PRICE SENSITIVE	794.46KB	Share
BIT Notification of cessation of securities - BIT
01/02/23		21.47KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	436.71KB	Share
BIT CLEANSING NOTICE
25/01/23		262.54KB	Share
BIT Application for quotation of securities - BIT
25/01/23		24.68KB	Share
BIT Change of Director's Interest Notice
29/11/22		250.15KB	Share
BIT Notification of cessation of securities - BIT
28/11/22		21.5KB	Share
BIT Cleansing Notice
25/11/22		97.91KB	Share
BIT Listed Options Information
25/11/22		98.9KB	Share
BIT Application for quotation of securities
25/11/22		358.97KB	Share
BIT Application for quotation of securities - BIT
25/11/22		29.22KB	Share
BIT Proposed issue of securities - BIT
24/11/22		27.45KB	Share
BIT Rights Issue Closed
24/11/22	PRICE SENSITIVE	174.24KB	Share
BIT Supplementary Prospectus
24/11/22	PRICE SENSITIVE	139.65KB	Share
BIT Cancel - Proposed issue of securities - BIT
22/11/22		38.86KB	Share
BIT Appendix 3B
21/11/22		753.77KB	Share
BIT $1.43M R&D rebate received
18/11/22	PRICE SENSITIVE	148.2KB	Share
BIT Results of Annual General Meeting
16/11/22		173.02KB	Share
BIT Chairman's Address and Presentation to AGM
16/11/22		370.97KB	Share
BIT Presentation to Investors
11/11/22		408.74KB	Share
BIT Clarification of Fractional Entitlements
07/11/22		112.37KB	Share
BIT Commencement of Rights Trading - BITRC
31/10/22	PRICE SENSITIVE	128.29KB	Share
BIT Letter to Shareholders
31/10/22		370.18KB	Share
BIT Prospectus
27/10/22	PRICE SENSITIVE	683.43KB	Share
BIT Renounceable Issue
27/10/22	PRICE SENSITIVE	190.28KB	Share
BIT Proposed issue of securities - BIT
27/10/22		39.21KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
24/10/22	PRICE SENSITIVE	422.98KB	Share
BIT Annual Report and Notice of Annual General Meeting
14/10/22		2.98MB	Share
BIT Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
04/10/22	PRICE SENSITIVE	181.16KB	Share
BIT Bit225 Covid-19 Human Study Commenced
14/09/22	PRICE SENSITIVE	175.41KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
23/08/22	PRICE SENSITIVE	154.11KB	Share
BIT Appendix 4G and Corporate Governance Statement
19/08/22		638.34KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
19/08/22	PRICE SENSITIVE	670.98KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/22	PRICE SENSITIVE	1.04MB	Share
BIT POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
30/05/22	PRICE SENSITIVE	130.47KB	Share
BIT BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS
02/05/22	PRICE SENSITIVE	353.01KB	Share
BIT Quarterly Cash Flow Report Appendix 4C
26/04/22	PRICE SENSITIVE	250.36KB	Share
BIT Quarterly Activities Report
26/04/22	PRICE SENSITIVE	137.32KB	Share
BIT $1.56M R&D Rebate Received
05/04/22	PRICE SENSITIVE	147.99KB	Share
BIT BIT225 Effectiveness Against COVID-19 in Animals
17/03/22	PRICE SENSITIVE	214.51KB	Share
BIT Half Yearly Report and Accounts
23/02/22	PRICE SENSITIVE	630.82KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	135.98KB	Share
BIT Quarterly Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	248.82KB	Share
BIT Update on Biotron HIV-1 And COVID-19 Programs
16/12/21		406.87KB	Share
BIT Notification of cessation of securities - BIT
06/12/21		21.5KB	Share
BIT BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS
25/11/21	PRICE SENSITIVE	594.07KB	Share
BIT Results of Meeting
23/11/21		159.5KB	Share
BIT Chairman's Address and Presentation to AGM
23/11/21		482.81KB	Share
BIT COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS
01/11/21	PRICE SENSITIVE	157.65KB	Share

REFRESH

1 2 3 4 5

(20min delay)
Last 2.0¢		Change -0.001(4.76%)		Mkt cap ! $18.04M

Open	High	Low	Value	Volume
2.1¢	2.1¢	2.0¢	$12.00K	600.2K

Buyers (Bids)

No.	Vol.	Price($)
5	972631	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.1¢	199783	1

View Market Depth

No.	Vol.	Price($)
5	972631	0.019
10	2364942	0.018
6	738000	0.017
11	1456225	0.016
4	635000	0.015

Price($)	Vol.	No.
0.021	199783	1
0.022	41868	2
0.023	506413	1
0.024	222185	3
0.025	600000	3

Last trade - 14.33pm 01/11/2024 (20 minute delay)


Last 2.0¢		Change -0.001 ( 4.76 %)
Open	High	Low	Volume
2.0¢	2.0¢	2.0¢	199442
Last updated 14.33pm 01/11/2024 ?

BIT (ASX) Chart

BIOTRON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available